IBRX Company Card: Cancer Vaccine's Cash-Burning Gamble

Data as of 2026-07-07. Source: US Stock VIP MCP (Alpha Vantage function set).

I. Company Snapshot

II. Core Business and Product Line

ImmunityBio focuses on developing memory T-cell cancer vaccines, aiming to fight multiple tumors without high-dose chemotherapy. Core assets:

• Anktiva (IL-15 superagonist, N-803): FDA-approved in 2024 for non-muscle-invasive bladder cancer (NMIBC); currently the main revenue engine.
• AdCTA (Antigen-Directed Cancer Vaccine): Indications being expanded.
• Nemtabrutinib and other small molecules / bispecific platforms: Early clinical stage.

III. Valuation and Profitability Core Metrics

IV. Multi-Year Income Statement (Annual)

*2018 COGS was -$3.11M, distorting gross profit; 2019 also had negative gross profit of $8.97M.

Key YoY Growth

Revenue structure showed a clear inflection point in 2024: from sub-million-dollar levels the previous year, breaking into tens of millions, then officially surpassing $100M in 2025—Anktiva commercialization is the main driver.

V. Balance Sheet (Annual + Recent)

Key Observations

• Shareholders' equity worsening year after year: Cumulative losses (retained earnings) reached -$4.36 billion in 2026 Q1, meaning the company has cumulatively "burned" $4.36 billion since inception.
• Cash wild swings: From 2023 peak of $265.5M → 2025 low of $88.3M → recovered to $205.2M in 2026 Q1, showing a typical "burn then refinance" cycle.
• Long-term debt climbing: Expanded from $254M in 2020 to $678M in 2026 Q1, with financial leverage continually increasing.

VI. Cash Flow Statement

Cash Flow Quality Analysis

1. Operating CF negative every year: 8-year total approximately -$2.06 billion, not a single year turned positive.
2. Financing CF is the only lifeline: 8-year total inflow of $2.24 billion (new shares + debt), operating losses almost 100% filled by financing.
3. 2025 "burn rate" slowed: Operating CF improved from -$391M in 2024 to -$305M, directly tied to revenue explosion, a positive signal.
4. SBC carries dilution pressure: Cumulative $219M SBC from 2021-2025, averaging ~15-20% of R&D expense annually, exerting dilution effects on per-share value.
5. Cash burn rate: Based on 2025 full-year operating CF of -$305M, monthly burn ~$25M; year-end 2025 cash of $88.3M theoretically gave less than 4 months of runway, and 2026 Q1 relied on $224M financing CF to refill to $205.2M.

VII. Recent Quarterly Momentum

Revenue increased for five consecutive quarters: $16.5M → $26.4M → $32.1M → $38.3M → $44.2M, clear sequential momentum. The Q1 2026 net loss surge was mainly due to one-time non-recurring items (refer to 10-Q notes for composition confirmation), and does not represent fundamental operational deterioration.

VIII. Valuation and Market Sentiment

IX. Risk Disclosures

1. Funding chain risk: Cumulative losses of $4.36 billion, negative shareholders' equity, year-end 2025 cash only $88.3M—the company essentially survives on financing; if the market turns bearish or new share issuance hits obstacles, operational continuity is directly threatened.
2. Dilution risk: Shares outstanding already at 1.047 billion, historical financing heavily relied on new issuance; each new round of financing will directly dilute per-share value.
3. Product concentration: Anktiva contributes the vast majority of revenue, indication expansion (NMIBC BCG-unresponsive cohorts, other cancer types) and competitor progress (e.g., Merck's Keytruda, Takeda's Adcetris-like immunotherapies) directly affect valuation.
4. Regulatory and clinical risk: Fierce competition in immunotherapy, Phase III data, FDA label expansion approvals all carry high uncertainty.
5. Gross margin volatility: 2025 Q3, Q4 gross margin dropped from 99% to 87-89%; if the trend expands, it will erode the hard-won operating leverage.
6. Volatility trap: Beta of 0.077 appears extremely low, but is actually distorted by the mathematical denominator (negative book value); 52-week stock range $1.95–$12.43, with a 6.4x amplitude, actual volatility is far higher than Beta suggests, and those with low risk tolerance should strictly control position size.

X. 3 Questions Worth Following Up

1. What is the clinical timeline for Anktiva's label-expansion indications? Beyond NMIBC, when will Phase II/III data for lung cancer, lymphoma, pancreatic cancer and other tumor types read out? This is the key catalyst for whether valuation can transition from P/S 70x toward "profitability".
2. What is the 2026 refinancing structure and dilution extent? Q1 2026 financing CF reached $223.9M, need to clarify whether this is debt, ATM offering, or PIPE? What are the average issuance price, subscribers, expected 12-month cash flow gap, and new share issuance cadence?
3. Is the gross margin decline a product mix issue or production cost issue? 2025 Q3-Q4 gross margin dropped from 99% to 87-89%, need to break down: is it due to promotional discounts, reimbursement structure changes, or actual COGS increase? If this trend expands, it will directly offset the operating leverage improvement brought by revenue growth.